Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2024-10-05 (pharmatutor.org)
Require Medical Safety Lead at Novartis
Bachelor of Science in Pharmacy, Bachelor of Science in Nursing, PharmD, PhD in relevant field or Medical Degree MBBS or MD required.
Read more
2024-09-14 (medicaldialogues.in)
CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and efficacy data with the DMC (Data Monitoring...
Read more
2024-09-14 (medicaldialogues.in)
CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and efficacy data with the DMC (Data Monitoring...
Read more
2024-02-01 (vidal.fr)
Availability of medicines in town and in hospital
Between January 26 and February 1, 2024, the National Medicines and Drug Safety Agency
Read more
2024-01-12 (statnews.com)
Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more
A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
Read more
2024-01-12 (statnews.com)
Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more
A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
Read more
2023-12-15 (smanewstoday.com)
Zolgensma may safely benefit older, heavier SMA children: Study
In a real-world study, Zolgensma treatment did not cause any serious long-term safety problems for a handful of heavier children with SMA.
Read more
2023-12-15 (smanewstoday.com)
Zolgensma may safely benefit older, heavier SMA children: Study
In a real-world study, Zolgensma treatment did not cause any serious long-term safety problems for a handful of heavier children with SMA.
Read more
2023-11-08 (healio.com)
BLOG: GA patients deserve better drug adoption
More than a decade ago, I told my wife’s grandfather that, despite all our advances in medicine, we didn’t have a treatment for his geographic atrophy.
Read more
2023-10-09 (suedkurier.de)
Weir: This is how the fire brigade rehearses dangerous operations under realistic conditions
Fire departments can also simulate difficult situations with a special fire container. Take a look behind the scenes of an exercise here.
Read more
2023-05-19 (hcplive.com)
Don't Miss a Beat: ESC Heart Failure Association Preview
In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.
Read more
2023-02-01 (fiercebiotech.com)
Novartis cans branaplam after seeing Huntington's safety signal, delays orphan drug over slow enrollment
Novartis has delivered the coup de grâce to its ailing branaplam program, stoppin | Novartis has delivered the coup de grâce to its ailing branaplam program, stopping development of the splicing modulator in Huntington’s disease in the wake of a safety signal.
Read more